<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586907</url>
  </required_header>
  <id_info>
    <org_study_id>17730</org_study_id>
    <secondary_id>J2R-MC-YAAB</secondary_id>
    <nct_id>NCT04586907</nct_id>
  </id_info>
  <brief_title>A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety of LY3537021 and any side&#xD;
      effects that might be associated with it in healthy participants and participants with type 2&#xD;
      diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3537021 gets into&#xD;
      the bloodstream and how long the body takes to eliminate it.&#xD;
&#xD;
      This study will last up to about 19 weeks including screening period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">December 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 119 (Part A) and Day 57 (Part B)</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3537021</measure>
    <time_frame>Predose Day 1 through Day 119 (Part A) and Day 57 (Part B)</time_frame>
    <description>PK: AUC of LY3537021</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3537021</measure>
    <time_frame>Predose Day 1 through Day 119 (Part A) and Day 57 (Part B)</time_frame>
    <description>PK: Cmax of LY3537021</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Healthy</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>LY3537021 (Part A/Healthy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3537021 administered subcutaneously (SC) to healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3537021 (Part A/Type 2 Diabetes)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3537021 administered SC to participants with type 2 diabetes mellitus (T2DM).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3537021 (Part B/Healthy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3537021 administered SC to healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3537021 (Part B/Type 2 Diabetes)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3537021 administered SC to participants with T2DM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3537021</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3537021 (Part A/Healthy)</arm_group_label>
    <arm_group_label>LY3537021 (Part A/Type 2 Diabetes)</arm_group_label>
    <arm_group_label>LY3537021 (Part B/Healthy)</arm_group_label>
    <arm_group_label>LY3537021 (Part B/Type 2 Diabetes)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy males or females not of childbearing potential, as determined&#xD;
             through medical history and physical examination&#xD;
&#xD;
          -  Contraceptive use by men should also be consistent with local regulations regarding&#xD;
             the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  Have a body mass index of 18.5 to 40 kilograms per square meter (kg/m²), inclusive&#xD;
&#xD;
          -  Have hemoglobin A1c level of less than or equal to (≤)6.5 percent (%)&#xD;
&#xD;
        Patients with Type 2 Diabetes Mellitus (T2DM):&#xD;
&#xD;
          -  Have T2DM for at least 6 months&#xD;
&#xD;
          -  For Part A, have a hemoglobin A1c value at screening of 6.5% to 11% and are treated&#xD;
             with diet and exercise alone or a stable dose of metformin for at least 3 months prior&#xD;
             to screening. For Part B, have hemoglobin A1c value at screening of 6.5% to 10% and&#xD;
             are treated with diet and exercise alone or a stable dose of metformin for at least 3&#xD;
             months prior to screening with or without 1 other OAM, such as DPP-IV inhibitors,&#xD;
             SGLT-2 inhibitors, or sulfonylureas&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the&#xD;
             investigator, increases the risks associated with participating in the study or may&#xD;
             confound ECG data analysis&#xD;
&#xD;
          -  Have a history of malignancy within 5 years prior to screening&#xD;
&#xD;
          -  Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis&#xD;
&#xD;
          -  Have evidence of significant active psychiatric disorder(s) as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Have undergone any form of bariatric surgery&#xD;
&#xD;
          -  Have donated blood of 450 milliliters (mL) or more in the past 3 months or any blood&#xD;
             donation within the past month from screening&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 21 units per week (males up to age&#xD;
             65 years) and 14 units per week (females and males above 65 years), or are unwilling&#xD;
             to stop alcohol consumption 24 hours prior to dosing until discharge from the&#xD;
             investigative site&#xD;
&#xD;
          -  Smoke &gt;10 cigarettes per day or the equivalent or are unable or unwilling to refrain&#xD;
             from nicotine during investigative site admission&#xD;
&#xD;
        Patients with T2DM:&#xD;
&#xD;
          -  Have had any of the following within the past 6 months prior to screening: myocardial&#xD;
             infarction, unstable angina, coronary artery bypass graft, percutaneous coronary&#xD;
             intervention (diagnostic angiograms are permitted), transient ischemic attack,&#xD;
             cerebrovascular accident or decompensated congestive heart failure, or currently have&#xD;
             New York Health Association Class III or IV heart failure&#xD;
&#xD;
          -  Are currently treated with or within the past 3 months had treatment with GLP-1&#xD;
             receptor agonists, or insulin&#xD;
&#xD;
          -  Have had severe hypoglycemic event in the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/7IMiImLoFJtACecUmt7d9Q</url>
    <description>A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus</description>
  </link>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

